Scarica l'app Stockscreener
1.95
1.52%
-0.03
Dopo l'orario di chiusura:
2.04
0.09
+4.62%
Precedente Chiudi:
$1.98
Aprire:
$2.03
Volume 24 ore:
25,644
Relative Volume:
0.50
Capitalizzazione di mercato:
$8.19M
Reddito:
$125.00K
Utile/perdita netta:
$-14.64M
Rapporto P/E:
-0.3774
EPS:
-5.1674
Flusso di cassa netto:
$-15.06M
1 W Prestazione:
+9.55%
1M Prestazione:
-5.34%
6M Prestazione:
-50.26%
1 anno Prestazione:
-79.52%
Intervallo 1D:
$1.95
$2.04
Intervallo di 1 settimana:
$1.75
$2.18
Portata 52W:
$1.70
$10.40
Imunon Inc Stock (IMNN) Company Profile
Nome
Imunon Inc
Settore
Industria
Telefono
(609) 896-9100
Indirizzo
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.95 | 8.32M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imunon Inc Borsa (IMNN) Ultime notizie
Form 4 Imunon Inc For: 7 July By Investing.com - Investing.com Canada
Imunon 1Q Loss/Shr 84c >IMNN - Moomoo
IMNNImunon Inc Latest SEC Filings - Finviz
IMUNON announces executive transition: Josh Blacher appointed interim CFO as Jeffrey Church retires - MSN
Imunon (IMNN) Reorganizes Financial Leadership Ahead of CFO Tran - GuruFocus
Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed - TipRanks
ImunonJeffrey Church To Retire As Interim CFO Effective July 1, 2026SEC Filing - TradingView
Imunon Names Josh Blacher Interim Chief Financial Officer - TipRanks
Imunon CFO Jeffrey Church to Retire; Josh Blacher Named Interim CFO - TradingView
Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO - Stock Titan
Imunon, Inc. Appoints Josh Blacher as Principal Financial Officer and Principal Accounting Officer, Effective July 1, 2026 - marketscreener.com
Insider Sell: Susan Eylward Sells 11,800 Shares of Imunon Inc (I - GuruFocus
Form 4 Imunon Inc For: 29 June By Investing.com - Investing.com South Africa
Imunon (IMNN) Chief Medical Officer granted 21,896 shares in lieu of 2025 cash bonus - Stock Titan
Imunon (IMNN) counsel gets stock bonus, then sells 11,800 shares - Stock Titan
Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant - Stock Titan
Imunon (IMNN) CEO awarded 67,150 shares instead of cash bonus - Stock Titan
Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN) - MSN
Enterprise value to EBITDA forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Price to earnings forward of Imunon, Inc. – DUS:CBO0 - TradingView
Price to sales forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Enterprise value to revenue forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Price to book forward of Imunon, Inc. – NASDAQ:IMNN - TradingView
Imunon, Inc. Actuals & Estimates (FWB:CBO0) - TradingView
Enterprise value to EBITDA forward of Imunon, Inc. – DUS:CBO0 - TradingView
Imunon, Inc. Actuals & Estimates (MUN:CBO0) - TradingView
Imunon, Inc. Actuals & Estimates (DUS:CBO0) - TradingView
Imunon, Inc. (IMNN) Presents at Life Sciences Virtual Investor ForumSlideshow (NASDAQ:IMNN) 2026-06-26 - Seeking Alpha
Imunon, Inc. Actuals & Estimates (NASDAQ:IMNN) - TradingView
A41CNR Forecast — Price Target — Prediction for 2027 - TradingView
IMNN Forecast — Price Target — Prediction for 2027 - TradingView
IMNN: IMNN-001 shows unprecedented survival benefit in ovarian cancer, advancing in Phase 3 trials - TradingView
Form 4 Imunon Inc For: 23 June By Investing.com - Investing.com South Africa
Form 4 Imunon Inc For: 23 June - Investing.com UK
Imunon (IMNN) executive chair granted 4,629 shares in lieu of cash pay - Stock Titan
Imunon (IMNN) CEO Stacy Lindborg gets 1,803-share stock grant in lieu of salary - Stock Titan
Imunon’s ovarian cancer trial continues after committee review By Investing.com - Investing.com India
Imunon (IMNN) Phase 3 Trial Receives Green Light from Data Monit - GuruFocus
Imunon (IMNN) Phase 3 Trial Receives Green Light from Data Monitoring Committee - GuruFocus
Imunon’s ovarian cancer trial continues after committee review - Investing.com
IMUNON’s Phase 3 OVATION 3 Trial in Advanced Ovarian Cancer Recommended to Continue by Independent Data Monitoring Committee - Quiver Quantitative
IMUNON ovarian cancer trial stays on track after safety review - Stock Titan
IMUNON to Present at the Life Sciences Investor Forum on June 25th - GlobeNewswire
Imunon Inc (IMNN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Imunon Inc (IMNN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Imunon Shareholders Expand Stock Incentive Plan, Back Governance - The Globe and Mail
Imunon Inc (IMNN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Imunon Inc (IMNN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Imunon Inc (IMNN) Institutional Confidence - TradingKey
Imunon Inc (IMNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Imunon Inc Azioni (IMNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Imunon Inc Azioni (IMNN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lindborg Stacy | President and CEO |
Sep 06 '25 |
Option Exercise |
0.00 |
1,667 |
0 |
3,584 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):